During the subsequent steps of the cancer-immunity cycle, EPHA5 mutations likely do not correlate with TAA presentation, as the MHC-I signature did not differ between patients with WT EPHA5 and those with mutated EPHA5. This evidence concerns the gene EPHA5 and cancer.